Y-mAbs Therapeutics, Inc. Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022.

Monoclonal antibodies have been a breakthrough treatment for cancer and other diseases. Now doctors are turning to them in the fight against COVID-19. Find out what this therapy is, how it works ...

Y-mAbs Therapeutics YMAB stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete Response ...

Cancer drug developer Y-mAbs Therapeutics (NASDAQ: YMAB) didn't exactly kick off the stock trading week on a high note. The company's shares closed the day more than 11% lower in price, following ...

In the assessment of 12-month price targets, analysts unveil insights for Y-mAbs Therapeutics, presenting an average target of $14.2, a high estimate of $22.00, and a low estimate of $7.00.

Y-mAbs Therapeutics Inc has a consensus price target of $17.14 based on the ratings of 16 analysts. The high is $26 issued by Canaccord Genuity on August 13, 2024 . The low is $7 issued by Morgan ...

Y-mAbs Therapeutics Inc. said it sold 6 million shares for $16 each in its initial public offering, raising $96 million. The cancer drug developer sold 6 million shares for $16 each.

Y-mAbs' shares fell 37% in premarket trading from $8.93 at market close on Friday to $5.62 on Monday morning. Y-mAbs Therapeutics FDA advisory committee neuroblastoma rare diseases Biotech.

Y-mAbs Therapeutics, Inc. Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 . The Company established two business units in January ...